Advertisement

Applied Psychophysiology and Biofeedback

, Volume 26, Issue 1, pp 23–37 | Cite as

The Ethical Use of Placebo Controls in Clinical Research: The Declaration of Helsinki

  • Theodore J. La Vaque
  • Thomas Rossiter
Article

Abstract

Medical ethicists have questioned the use of no-treatment (placebo and sham procedure) controlled studies of new therapies when safe and effective standard therapies are available for use as an active or “equivalence” control. Current ethical principles of conduct for biomedical research specifically prohibit designs that withhold or deny “the best proven diagnostic and therapeutic” treatment to any participant in a clinical study, including those individuals who consent to randomization into a control group. Studies of psychophysiological therapies are often criticized on the grounds they lack a placebo or sham treatment control group. This paper briefly reviews the history of the problem and discusses the ethical standards that govern human research as derived from the Nuremberg Code and the Declaration of Helsinki. An examination of the problem with regard to research involving EEG biofeedback therapy for Attention-Deficit/Hyperactivity Disorder, Traumatic Brain Injury, and depression serves to highlight the issues. It is concluded that the active treatment control (treatment equivalence) design is most appropriate for those clinical studies examining disorders for which there is a known, effective treatment. Sham- or placebo-controlled studies are ethically acceptable for those disorders for which no effective treatment is available.

ethics of clinical research EEG biofeedback sham treatment controls placebo treatment controls active treatment controls ADHD TBI depression Declaration of Helsink 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. Addington, D., Williams, R., Lapierre, Y., & el-Guebaly, N. (1997). Placebos in clinical trials of psychotropic medication. Canadian Journal of Psychiatry, 42(3), 6.Google Scholar
  2. Alderson, P. (1996). Equipoise as a means of managing uncertainty: Personal, communal and proxy. Journal of Medical Ethics, 22(3), 135-139.Google Scholar
  3. Alves, W. A., & Macciocchi, S. N. (1996). Ethical considerations in clinical neuroscience. Current concepts in neuroclinical trials. Stroke, 27(10), 1903-1909.Google Scholar
  4. Annas, G., & Grodin, M. (1998). Human rights and maternal-fetal HIV transmission prevention trials in Africa. American Journal of Public Health, 88(4), 560-563.Google Scholar
  5. Antonuccio, D. O., Danton, W. G., & DeNelsky, G. Y. (1995). Psychotherapy vs. medication for depression: Challanging the conventional wisdom with data. Professional Psychology: Research and Practice, 26, 574-585.Google Scholar
  6. Antonuccio, D. O., Danton, W. G., DeNelsky, G. Y., Greenberg, R. P., & Gordon, J. S. (1999). Raising questions about antidepressants. Psychotherapy and Psychosomatics, 68(1), 3-14.Google Scholar
  7. Appelbaum, P. S. (1997). Rethinking the conduct of psychiatric research. Archives of General Psychiatry, 54(2), 117-120.Google Scholar
  8. Arnold, L. E. (1998, November). Treatment alternatives for attention deficit hyperactivity disorder. Paper presented at the NIH Consensus Development Conference on Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder, Bethesda, MD.Google Scholar
  9. Aspinall, R., & Goodman, N. W. (1995). Denial of effective treatment and poor quality of clinical information in placebo controlled trials of ondansetron for postoperative nausea and vomiting: A review of published trials. British Medical Journal, 311(7009), 844-846.Google Scholar
  10. Barkley, R. A. (1990). Attention deficit hyperactivity disorder: A handbook for diagnosis and treatment. New York: Guilford Press.Google Scholar
  11. Barkley, R. A. (1992). Is EEG biofeedback treatment effective for ADHD children? Ch.A.D.D.er Box, 5-11.Google Scholar
  12. Beardsley, T. (1998). Coping with HIV's ethical dilemmas. Scientific American (July), 106-107.Google Scholar
  13. Benedek, T. G. (1978). The 'Tuskegee Study' of syphilis: analysis of moral versus methodologic aspects. Journal of Chronic Disease, 31(1), 35-50.Google Scholar
  14. Blackwelder, W. C. (1982). “Proving the null hypothesis” in clinical trials. Controlled Clinical Trials, 3(4), 345-353.Google Scholar
  15. Bloom, B. R. (1998). The highest attainable standard: Ethical issues in AIDS vaccines. Science, 279(5348), 186-188.Google Scholar
  16. Brawley, O. W. (1998). The study of untreated syphilis in the negro male. International Journal of Radiation Oncology Biology and Physics, 40(1), 5-8.Google Scholar
  17. Brennan, T. A. (1999). Proposed revisions to the Declaration of Helsinki-Will they weaken the ethical principles underlying human research? New England Journal of Medicine, 341(7), 527-530.Google Scholar
  18. Brown, R. T., Wynne, M. E., Borden, K. A., Clingerman, S. R., Geniesse, R., & Spunt, A. L. (1986). Methylphenidate and cognitive therapy in children with attention deficit disorder. A double-blind trial. Developmental and Behavioral Pediatrics, 7, 163-172.Google Scholar
  19. Byman, B. (1989). Bitterfruit. The legacy of Nazi medical experiments. Minnesota Medicine, 72(10), 580-586.Google Scholar
  20. Caldwell, J. G., Price, E. V., Schroeter, A. L., & Fletcher, G. F. (1973). Aortic regurgitation in the Tuskegee study of untreated syphilis. Journal of Chronic Disease, 26(3), 187-194.Google Scholar
  21. Caplan, A. L. (1992). Twenty years after. The legacy of the Tuskegee Syphilis Study. When evil intrudes. Hastings Center Report, 22(6), 29-32.Google Scholar
  22. Capron, A. M. (1999). Ethical and human-rights issues in research on mental disorders that may affect decisionmaking capacity. New England Journal of Medicine, 340(18), 1430-1434.Google Scholar
  23. Chamblis, D. L. (1995). Report of the task force on promotion and dissemination of psychological procedures. Clinical Psychologist, 48(1), 3-23.Google Scholar
  24. Cobb, W. M. (1973). The Tuskegee syphilis study. Journal of the National Medical Association, 65(4), 345-348.Google Scholar
  25. Collier, J. (1995). Confusion over use of placebos in clinical trials (editorial). British Medical Journal, 311(7009), 821-822.Google Scholar
  26. De Deyn, P. P., & D'Hooge, R. (1996). Placebos in clinical practice and research. Journal of Medical Ethics, 22(3), 140-146.Google Scholar
  27. Dove, A. (1999). WMA to revise medical research guidelines (news). Nature Medicine, 5(6), 598.Google Scholar
  28. Edgar, H. (1992). Twenty years after. The legacy of the Tuskegee Syphilis Study. Outside the community. Hastings Center Report, 22(6), 32-35.Google Scholar
  29. Edwards, S. J. L., Lilford, R. J., Braunholtz, D. A., Jackson, J. C., Hewison, J., & Thornton, J. (1998). Ethical issues in the design and conduct of randomized controlled trials. Health Technology Assessment, 2(15), 1-134.Google Scholar
  30. Fisher, R. L., & Fisher, S. (1996). Antidepressants for children. Is scientific support necessary? Journal of Nervous and Mental Disease, 184(2), 99-102.Google Scholar
  31. Flap on NEJM board over ethics articles [news]. (1997). Science, 278(5336), 211.Google Scholar
  32. Freedman, B. (1990). Placebo-controlled trials and the logic of clinical purpose. IRB: Revue of Human Subjects Research, 12(6), 1-6.Google Scholar
  33. Freedman, B., Glass, K. C., & Weijer, C. (1996). Placebo orthodoxy in clinical research. II: Ethical, legal, and regulatory myths. Journal of Law, Medicine & Ethics, 24(3), 252-259.Google Scholar
  34. Freedman, B., Weijer, C., & Glass, K. C. (1996). Placebo orthodoxy in clinical research. I: Empirical and methodological myths. Journal of Law, Medicine & Ethics, 24(3), 243-251.Google Scholar
  35. Freeman, T., Vawter, D., Leaverton, P., Godbold, J., Hauser, R., & Goetz, C. (1999). Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease. New England Journal of Medicine, 341, 988-992.Google Scholar
  36. Fuchs, T. (1999). Aufmerksamkeit und neurofeedback: evaluation eines psychophysiologischen eeg-biofeedbackbehandlungs programms bei aufmerksamkeits und hyperaktivitatsstorungen in kinesalter [Attention and neurofeedback: An evaluation of a psychophysiological EEG biofeedback treatment program for childhood attention-deficit/hyperactivity disorders]. Regensburg: Roderer. [The dissertation, in German, and the abstract, in English, are available at www.eegspectrum.com]Google Scholar
  37. Glantz, L. H. (1996). Conducting research with children: Legal and ethical issues. Journal of the American Academy of Child and Adolescent Psychiatry, 35(10), 1283-1291.Google Scholar
  38. Health and Human Services. (1999). Mental health: A report of the Surgeon General (017-024-01653-S). Washington, DC: U.S. Government Printing Office.Google Scholar
  39. Jacobson, N. S., & Hollon, S. D. (1996). Cognitive-behavior therapy versus pharmacotherapy: Now that the jury's returned its verdict, it's time to present the rest of the evidence. Journal of Consulting and Clinical Psychology, 64(1), 74-80.Google Scholar
  40. Jarrett, R. B., Schaffer, M., McIntire, D., Witt-Browder, A., Kraft, D., & Risser, R. C. (1999). Treatment of atypical depression with cognitive therapy or phenelzine: A double-blind, placebo-controlled trial. Archives of General Psychiatry, 56(5), 431-437.Google Scholar
  41. Lehmann, H. E. (1979). Problems with ethical aspects of psychotropic drug use. Progress in Neuropsychopharmacology, 3(1-3), 271-275.Google Scholar
  42. Lehrman, N. S., & Sharav, V. H. (1997). Ethical problems in psychiatric research. The Journal of Mental Health Administration, 24(2), 227-250.Google Scholar
  43. Levine, R. (1998). The “Best Proven Therapeutic Method” standard in clinical trials in technologically developing countries. The Journal of Clinical Ethics, 9(2), 167-172.Google Scholar
  44. Levine, R. J. (1999). The need to revise the Declaration of Helsinki. New England Journal of Medicine, 341(7), 531-534.Google Scholar
  45. Lurie, P. (1999, April). The use of placebos in clinical trials and the ethics of the use of placebos. Paper presented at the Committee for Advanced Scientific Education Seminar Series, Rockville, MD.Google Scholar
  46. Lurie, P., & Wolfe, S. (1997). Unethical trials of interventions to reduce perinatal transmission of the Human Immunodeficiency Virus in developing countries. New England Journal of Medicine, 337(12), 853-856.Google Scholar
  47. Macklin, R. (1999). The ethical problems with sham surgery in clinical research. NewEngland Journal of Medicine, 341(13), 992-996.Google Scholar
  48. Malone, R. P., & Simpson, G. M. (1998). Use of placebos in clinical trials involving children and adolescents. Psychiatric Services, 49(11), 1413-1414, 1417.Google Scholar
  49. Malt, U. F., Robak, O. H., Madsbu, H. P., Bakke, O., & Loeb, M. (1999). The Norwegian naturalistic treatment study of depression in general practice (NORDEP)-I: Randomised double blind study. British Medical Journal, 318(7192), 1180-1184.Google Scholar
  50. Marquis, D. (1999). How to resolve an ethical dilemma concerning randomized clinical trials. New England Journal of Medicine, 341(9), 691-692.Google Scholar
  51. Michels, R. (1999). Are research ethics bad for our mental health? New England Journal of Medicine, 340(18), 1427-1430.Google Scholar
  52. Olanow, C. W., Kordower, J. H., & Freeman, T. B. (1996). Fetal nigral transplantation as a therapy for Parkinson's disease. Trends in Neuroscience, 19, 102-109.Google Scholar
  53. Piot, P. (1998). The science of AIDS: A tale of two worlds. Science, 280(June), 1844-1845.Google Scholar
  54. Quitkin, F. M. (1999). Placebos, Drug Effects, and Study Design: A Clinician's Guide. American Journal of Psychiatry, 156(6), 829-836.Google Scholar
  55. Ramsay, S. (1999). WMA postpones decision to revise Declaration of Helsinki.World Medical Association [news]. Lancet, 354(9182), 928.Google Scholar
  56. Rapoport, J. L., Buchsbaum, M. S., Weingartner, H., Zahn, T., Ludlow, C., & Mikkelsen, E. J. (1980). Dextroamphetamine: Its cognitive and behavioral effects in normal and hyperactive boys and normal men. Archives of General Psychiatry, 37, 933-943.Google Scholar
  57. Rapoport, J. L., Bucksbaum, M. S., Zahn, T. P., Weingartner, H., Ludow, C., & Mikkelsen, E. J. (1978). Dextroamphetamine: Cognitive and behavioral effects in normal prepuberal boys. Science, 199, 560-563.Google Scholar
  58. Rogers, M. F., & Shaffer, N. (1999). Reducing the risk of maternal-infant transmission of HIV by attacking the virus. New England Journal of Medicine, 341(6), 441-442.Google Scholar
  59. Rossiter, T. R. (1998). Patient-directed neurofeedback for AD/HD. Journal of Neurotherapy, 2, 54-64.Google Scholar
  60. Rossiter, T. R., & La Vaque, T. J. (1995). A comparison of EEG biofeedback and psychostimulants in treating attention deficit hyperactivity disorders. Journal of Neurotherapy, 1, 48-59.Google Scholar
  61. Rothman, K. J., & Michels, K. B. (1994). The continuing unethical use of placebo controls. New England Journal of Medicine, 331(6), 394-397.Google Scholar
  62. Spencer, T., Wilens, T., Biederman, J., Faraone, S. V., Ablon, J. S., & Lapey, K. (1995). A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Archives of General Psychiatry, 52, 434-443.Google Scholar
  63. Stein, C. M., & Pincus, T. (1999). Placebo-controlled studies in rheumatoid arthritis: Ethical issues. Lancet, 353(9150), 400-403.Google Scholar
  64. Striefel, S. (1998). Is EEG biofeedback Per Se Experimental? Biofeedback, 26(4), 4-6, 12.Google Scholar
  65. Studdert, D. M., & Brennan, T. A. (1998). Clinical trials in developing countries: Scientific and ethical issues. Medical Journal of Australia, 169(10), 545-548.Google Scholar
  66. Swartwood, M. O., Swartwood, J. N., Lubar, J. F., Timmermann, D. L., Zimmerman, A. W., & Muenchen, R. A. (1998). Methylphenidate effects on EEG, behavior, and performance in boys with ADHD. Pediatric Neurology, 18(3), 244-250.Google Scholar
  67. Taubes, G. (1995). Use of placebo controls in clinical trials disputed. Science, 267(January), 25, 26.Google Scholar
  68. Temple, R. (1999, April). The use of placebos in clinical trials and the ethics of the use of placebos. Paper presented at the Committee for Advanced Scientific Education Seminar Series, Rockville, MD.Google Scholar
  69. Temple, R. J. (1997). When are clinical trials of a given agent vs. placebo no longer appropriate or feasible? Controlled Clinical Trials, 18(6), 613-620; discussion 661-666.Google Scholar
  70. Thatcher, R. W. (2000). EEG operant conditioning (biofeedback) and traumatic brain injury. Clinical Electroencephalography, 31(1), 38-44.Google Scholar
  71. Weijer, C. (1999). Placebo-controlled trials in schizophrenia: Are they ethical? Are they necessary? Schizophrenia Research, 35(3), 211-218; discussion 227-236.Google Scholar
  72. Wender, P. H., Reimherr, F. W., Wood, D., & Ward, M. (1985). A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults. American Journal of Psychiatry, 142, 547-552.Google Scholar
  73. Woodman, R. (1999). Storm rages over revisions to Helsinki Declaration [news]. British Medical Journal, 319(7211), 660.Google Scholar
  74. World Medical Association Declaration of Helsinki. (1997). Recommendations guiding physicians in biomedical research involving human subjects. Journal of the American Medical Association, 277(11), 925-926.Google Scholar
  75. Zeiner, P., Bryhn, G., Bjercke, C., Truyen, K., & Strand, G. (1999). Response to methylphenidate in boys with attention-deficit hyperactivity disorder. Acta Paediatrica Scandinavia, 88(3), 298-303.Google Scholar

Copyright information

© Plenum Publishing Corporation 2001

Authors and Affiliations

  1. 1.Clinical Psychophysiology CenterRogers Memorial HospitalMilwaukeeUSA
  2. 2.The Stress ClinicGreen BayUSA
  3. 3.The Stress ClinicGreen BayUSA
  4. 4.The Biofeedback CenterGreen BayUSA

Personalised recommendations